ArticleFrontiers in pharmacology2026

EZH2 blockade reverses doxorubicin resistance by inducing metabolic vulnerability and enhancing DNA damage in breast cancer.

Xiaomin Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.